Actively Recruiting
Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection
Led by University of Liege · Updated on 2024-05-09
20
Participants Needed
1
Research Sites
224 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The overall objective of the study is to evaluate the safety and efficacy of MSC therapy combined with best supportive care in hospitalized patients with COVID-19.
CONDITIONS
Official Title
Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female patients aged 18 to 70 years
- Diagnosed with COVID-19 pneumonia confirmed by microbiological or radiological tests
- Extensive interstitial pneumonia shown on CT scan within 10 days before randomization
- Positive COVID-19 PCR test within 14 days before inclusion or positive SARS-CoV2 PCR or serology within 14 days after inclusion
- Require oxygen support with SpO2 ≤ 93% on room air, either in standard or intensive care unit, including mechanical ventilation for less than or equal to 7 days or 7 to 14 days with persistent high inflammation
- Patient or legal representative provides written informed consent
You will not qualify if you...
- Current pregnancy or women of childbearing potential not using effective contraception
- Receiving extracorporeal membrane oxygenation (ECMO)
- Limitations to intensity of care or life expectancy under 24 hours
- Known allergy to investigational medicinal product components
- Active secondary infection
- Any malignancy (except non-melanoma skin cancer) within 2 years before inclusion
- Pre-existing thrombo-embolic disease
- Signs of active drug or alcohol dependence, serious illness, mental illness, or other factors interfering with study compliance
- Serious medical conditions or abnormal lab tests judged unsafe for study participation
- Participation in another clinical trial (compassionate use of COVID-19 drugs allowed)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU de Liège
Liège, Belgium, 4000
Actively Recruiting
Research Team
Y
Yves Beguin, MD,PhD
CONTACT
A
Audrey Janssen
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here